ImageVerifierCode 换一换
格式:PDF , 页数:11 ,大小:2.61MB ,
资源ID:2571123      下载积分:10 积分
快捷下载
登录下载
邮箱/手机:
温馨提示:
快捷下载时,用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)。 如填写123,账号就是123,密码也是123。
特别说明:
请自助下载,系统不会自动发送文件的哦; 如果您已付费,想二次下载,请登录后访问:我的下载记录
支付方式: 支付宝扫码支付 微信扫码支付   
验证码:   换一换

加入VIP,免费下载
 

温馨提示:由于个人手机设置不同,如果发现不能下载,请复制以下地址【https://www.wnwk.com/docdown/2571123.html】到电脑端继续下载(重复下载不扣费)。

已注册用户请登录:
账号:
密码:
验证码:   换一换
  忘记密码?
三方登录: QQ登录  

下载须知

1: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。
2: 试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。
3: 文件的所有权益归上传用户所有。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 本站仅提供交流平台,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

版权提示 | 免责声明

本文(基于坏死性凋亡相关长链非编...预后模型及药物治疗反应分析_张玉俊.pdf)为本站会员(哎呦****中)主动上传,蜗牛文库仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知蜗牛文库(发送邮件至admin@wnwk.com或直接QQ联系客服),我们立即给予删除!

基于坏死性凋亡相关长链非编...预后模型及药物治疗反应分析_张玉俊.pdf

1、安 徽 医 药 Anhui Medical and Pharmaceutical Journal 2023 Aug,27(8)基于坏死性凋亡相关长链非编码RNA构建肝细胞癌预后模型及药物治疗反应分析张玉俊1,朱琳2,赵璇1,地力亚尔 吾斯曼江1,王岩2作者单位:1新疆医科大学公共卫生学院,新疆维吾尔自治区 乌鲁木齐830054;2新疆医科大学附属肿瘤医院,新疆维吾尔自治区 乌鲁木齐830011通信作者:王岩,女,副教授,硕士生导师,研究方向为肿瘤流行病学,Email:基金项目:新疆维吾尔自治区自然科学基金项目(2021D01C379);省部共建中亚高发病成因与防治国家重点实验室开放课题项目(S

2、KL-HIDCA-2020-ER3,SKL-HIDCA-2020-33)摘要:目的 使用坏死性凋亡相关长链非编码RNA(NRLs)构建肝细胞癌(HCC)预后模型并分析不同风险组间药物敏感性差异,为HCC病人预后预测和临床个体化治疗提供理论依据。方法 从癌症基因组图谱(TCGA)数据库中下载HCC病人的RNA测序数据和临床信息。采用共表达网络分析鉴定NRLs。使用单变量Cox回归和LASSO-Cox回归构建预后模型,并在测试集和整个集合中进行验证。运用生存分析、受试者操作特征(ROC)曲线、临床病理分层相关性分析、多变量Cox回归、列线图和校准曲线来评估预后模型。随后,采用基因集富集分析(GSE

3、A)不同风险群体间生物过程和功能的差异。使用单样本基因集富集分析(ssGSEA)来探讨不同风险群体与肿瘤免疫、浸润之间的关系,并采用Pearson相关分析HCC病人预后特征与免疫检查点表达的相关性。最后,使用药物敏感性分析20种化疗药物在不同风险群体中的IC50值。结果 构建了由4个NRLs(ZFPM2-AS1、MKLN1-AS、LINC01116、AP003390.1)组成的风险评分(NRLs risk-Score)预后特征,并根据风险评分中位值将病人划分为高风险组和低风险组。生存分析表明,NRLs低风险组的总生存期(OS)显著高于高风险组;与临床病理特征相比,NRLs risk-Score

4、具有更高的诊断效率,受试者操作特征曲线下面积(AUC)为0.74;临床病理变量分层生存分析表明,高风险组病人OS显著低于低风险组;多变量Cox结果显示,分期(Stage)和NRLs risk-Score可作为HCC病人的独立预后因子,结合临床病理学特征和NRLs risk-Score的列线图显示出较好的预测性能。GSEA分析表明,癌症相关通路主要在高风险组中富集。ssGSEA结果显示,NRLs预测特征与HCC病人的免疫状态显著相关。免疫检查点分析结果显示,高风险组病人的免疫检查点表达较高,表明可能受益于检查点阻滞剂免疫疗法的高风险组HCC病人中免疫功能更为活跃。化疗药物敏感性分析结果显示,16

5、种化疗药物的IC50值在高低风险组间存在差异。结论 4个NRLs的风险特征有助于评估HCC病人预后和分子特征,可用于进一步优化HCC的个性化治疗和管理策略。关键词:癌,肝细胞;坏死性凋亡;长链非编码RNA;肿瘤免疫微环境;总生存期Prognostic model construction and drugtherapy response analysis of hepatocellular carcinoma based on necroptosis-related long noncoding RNAZHANG Yujun1,ZHU Lin2,ZHAO Xuan1,DiliyaerWusim

6、anjiang1,WANG Yan2Author Affiliations:1Public Health Institute of Xinjiang Medical University,Urumqi,Xinjiang Uyghur Autonomous Region 830054,China;2Afliated Tumor Hospital,Xinjiang Medical University,Urumqi,Xinjiang Uyghur Autonomous Region 830011,ChinaAbstract:Objective To construct a prognostic m

7、odel of hepatocellular carcinoma(HCC)using necroptosis-related long noncoding RNAs(NRLS)and analyze the difference of drug sensitivity among different risk groups,so as to provide a theoretical basis for prognosis prediction and clinical individualized treatment of HCC patients.Methods RNA sequencin

8、g data and clinical information of HCC patients were downloaded from the cancer genome atlas(TCGA)database.NRLS were identified by co-expression network analysis.A prognostic model was constructed using univariate Cox regression and lasso Cox regression and validated in the test set and whole set.Su

9、rvival analysis,receiver operating characteristic curve(ROC),stratified correlation analysis with clinicopathology,multivariate Cox regression,nomogram and calibration curve were used to evaluate the prognostic model.Subsequently,gene set enrichment analysis(GSEA)was employed to investigate the diff

10、erences in biological processes and functions among different risk groups.Single sample gene set enrichment analysis(ssGSEA)was used to explore the relationship between different risk groups and the tumor microenvironment,and Pearson correlation was employed to analyze the correlation between predic

11、tive features and immune checkpoint expression 临床医学引用本文:张玉俊,朱琳,赵璇,等.基于坏死性凋亡相关长链非编码RNA构建肝细胞癌预后模型及药物治疗反应分析 J.安徽医药,2023,27(8):1595-1601.DOI:10.3969/j.issn.1009-6469.2023.08.023.1595网络首发时间:2023-07-06 13:11:18网络首发地址:https:/ 徽 医 药 Anhui Medical and Pharmaceutical Journal 2023 Aug,27(8)in HCC patients.Fina

12、lly,the IC50 values of 20 chemotherapeutic agents in different risk groups were analyzed using drug sensitivity.Results A risk score(NRLS risk-score)prognostic signature consisting of four NRLS(ZFPM2-AS1,MKLN1-AS,LINC01116,AP003390.1)was constructed,and patients were assigned into high-and low-risk

13、groups according to the median risk score values.Survival analysis showed that the overall survival(OS)of the low-risk group with NRLS was significantly longer than that of the high-risk group.Compared with clinicopathological variables,the NRLS risk score signature had higher diagnostic efficiency

14、with an area under the receiver operating characteristic curve(AUC)of 0.74.Survival analysis stratified by clinicopathological variables showed that OS of patients in the high-risk group was significantly lower than that in the low-risk group.Multivariate Cox results showed that stage and NRLS risk-

15、score could serve as independent prognostic factors for HCC patients,and the combination of clinicopathological features and NRLS risk-score histogram showed good predictive performance.GSEA analysis indicated that cancer-related pathways were mainly enriched in the high-risk group.The ssGSEA result

16、s showed that the NRLS predictive signature was significantly associated with the immune status of HCC patients.The results of immune checkpoint analysis showed that the expression of immune checkpoints in patients with high-risk group was higher,indicating that the immune function of HCC patients in high-risk group who may benefit from checkpoint blocker immunotherapy was more active.The results of drug sensitivity analysis showed that the IC50 values of 16 chemotherapeutic drugs differed betwe

copyright@ 2008-2023 wnwk.com网站版权所有

经营许可证编号:浙ICP备2024059924号-2